WCN25-4361 COMPARING DESIDUSTAT – A HYPOXIA INDUCIBLE FACTOR STABILIZER AND ERYTHROPOIETIN STIMULATING AGENTS IN TREATMENT OF ANEMIA IN HEMODIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE

Anemia in chronic kidney disease is a multifactorial disease which significantly affects the quality of life and overall health of patients. It is mainly caused by erythropoietin deficiency, inflammatory process and increase hepcidin leading to impaired absorption of iron for the GI tract, accumulation of uremic toxins and reduced red cell life span. Anemia is diagnosed in adults with CKD when the Hb concentration is <13.0 g/dl in males and <12.0 g/dl in females. Currently, supplemental iron and recombinant human erythropoietin (EPO) consist of majority of the prescriptions for the management of anemia in CKD.